NMTC - NeuroOne posts data from initial long-term testing of thin film electrode technology

NeuroOne Medical Technologies (NMTC +11.4%) is trading higher after announcing that the company successfully concluded initial pre-clinical testing designed to assess the long-term recording capabilities of its platform thin film electrode technology. NeuroOne (NASDAQ:NMTC) is advancing the minimally invasive thin-film electrodes to help the diagnosis and treatment of multiple neurological indications. According to test results, NeuroOne's electrodes managed to overcome the environmental factors that could lead to device failure or malfunction, a known challenge in the development of thin-film electrode technology. The data support the potential expansion of the use of these electrodes in the long-term recording for neurological conditions such as epilepsy and Parkinson's disease, NeuroOne (NMTC) CEO, Dave Rosa, remarked. Read: With a Hold rating on NeuroOne (NMTC), Seeking Alpha contributor Avisol Capital Partners takes a closer look at the technology.

For further details see:

NeuroOne posts data from initial long-term testing of thin film electrode technology